PLRZ News & Events

Polyrizon announced the production of a Good Manufacturing Practice batch of clinical trial material for its lead product candidate. This milestone follows the Company's previously announced manufacturing agreement with Eurofins CDMO AmatsiAquitaine established to support the supply of clinical trial material for Polyrizon's clinical development program. The GMP manufacturing milestone represents a key step in Polyrizon's clinical development program and supports the company's preparations for a planned clinical study in the United States later this year. The GMP batch was manufactured following the production of two prior development batches, which demonstrated batch-to-batch consistency and product stability over time, supporting the robustness and reproducibility of the manufacturing process.The CTM batch was produced in compliance with applicable GMP standards in collaboration with Eurofins CDMO AmatsiAquitaine S.A.S, and will be used to support upcoming clinical activities and regulatory submissions related to the study.

Polyrizon announced results from a comparative study evaluating the regional nasal deposition profile of its naloxone formulation versus a commercial reference product. The study was conducted at the University of Parma's Biopharmanet-TEC research center under the scientific supervision of Prof. Fabio Sonvico. The laboratory specializes in the research and development of intranasally administered technologies. Key Findings: Polyrizon's advanced nasal formulation achieved 94.6% deposition in the nasal vestibule and upper turbinate, a highly vascularized region that may support rapid systemic absorption and potentially enhance the onset and bioavailability of intranasally administered drugs. In comparison, the reference commercial product delivered only 79.6% to the same nasal cavity area. Polyrizon's formulation also showed significantly lower deposition in the lower turbinate region, potentially reducing posterior runoff and unintended drainage toward the nasopharynx, which may support improved dosing consistency and systemic delivery efficiency.

Polyrizon recently announced the signing of a non-binding Memorandum of Understanding with Arrow Aviation, a global private aviation company. Under the terms of the MOU, Polyrizon intends to acquire a 51% stake in Arrow Aviation on a fully diluted basis through a cash investment of approximately $5.8M, marking a strategic expansion into the high-growth private aviation sector. Arrow Aviation has annual unaudited revenues of approximately $19M and adjusted EBITDA of approximately $3M. The proposed transaction includes ancillary arrangements, such as the transfer of a Hawker 800 aircraft valued at $3.5M to Arrow Aviation by a third party, in exchange for a convertible note (convertible in Polyrizon ordinary shares) issued by Polyrizon. Additionally, existing Arrow Aviation shareholders will forgive outstanding shareholder debts owed by Arrow Aviation in return for convertible notes (convertible in Polyrizon ordinary shares) from Polyrizon, enabling Arrow Aviation to emerge debt-free from institutional obligations post-closing. The MOU also outlines mutual call and put options on the remaining 49% of Arrow Aviation's shares, exercisable after two years, based on agreed valuation multiples tied to financial metrics like EBITDA or revenue, which may result in Polyrizon acquiring 100% of Arrow Aviation on a fully diluted basis. The signing of a definitive agreement is expected to occur within 30 days of the MOU, subject to due diligence, after which the closing of the acquisition would be expected to occur following the satisfaction of customary closing conditions.